Form 4: Emergent BioSolutions CFO Receives RSU Grant

CFO Richard S. Lindahl acquired 162,680 restricted stock units following shareholder approval of the company's incentive plan.

Summary

• Richard S. Lindahl, EVP and CFO of Emergent BioSolutions, was granted 162,680 restricted stock units (RSUs).
• The grant was initially approved by the Compensation Committee on March 2, 2026, contingent upon shareholder approval of the Amended Stock Incentive Plan.
• Shareholders approved the plan on April 29, 2026, triggering the formal issuance of the units.
• The RSUs vest in three equal annual installments, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Successful shareholder approval of the Amended Stock Incentive Plan provides the company with necessary tools for talent retention.

Negatives

• The issuance of 162,680 RSUs results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is contingent upon continued service, creating potential retention risk if the executive departs before the three-year period concludes.

Future Outlook

The RSUs will vest in three annual installments starting from the anniversary of the approval date, contingent on the executive's continued employment with the company.

Management Comments

• The grant is subject to the terms of the Amended Stock Incentive Plan and the specific grant agreement.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to align executive incentives with long-term corporate performance and shareholder value.

Comparison to Industry Standards

• The use of three-year vesting schedules for executive equity grants is consistent with standard corporate governance practices in the U.S. biotech industry.
• Granting equity following shareholder approval of incentive plans is a standard regulatory requirement for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon the vesting of the RSUs.
• Executive: Increased alignment with company performance through equity ownership.

Next Steps

• Vesting of the first installment of RSUs on the anniversary of the April 29, 2026 approval date.

Key Dates

Keywords

Emergent BioSolutions, EBS, CFO, Insider Transaction, Restricted Stock Units, Equity Compensation